Abstract: The invention relates to a method for detecting increased susceptibility to tumours by specifically detecting a polymorphism in the position 354 A ? G in the exon 12 of the human murine double minute-2 (MDM2) gene. Said polymorphism represents a hereditary marker for increased risk of cancer in humans. The invention also relates to the use of said tumour susceptibility marker for developing in vitro and in vivo test systems which integrate said markers, in a specific manner, into diagnostic, prognostic and possibly therapeutic methods.

Abstract: The subject of the invention are formulations not containing chaotropic components for isolating nucleic acids with binding to a solid phase, in particular of DNA, from optional complex starting materials and quantities containing a lysis/binding buffer system which comprises at least one antichaotropic salt component, a solid phase and wash and elution buffers known as such. The lysis/binding buffer system may be an aqueous solution or a solid formulation in reaction vessels ready for use. All carriers used for isolation by means of chaotropic reagents, preferably glass fiber mats, glass membranes, silica carriers, ceramics, zeolites or materials showing negatively functionalised surfaces or chemically modified surfaces which may be converted to a negative charge potential may serve as a solid phase.